培美曲塞-顺铂与多西他赛-顺铂治疗非小细胞肺癌的疗效

Efficacy of pemetrexed-cisplatin and docetaxel race-cisplatin in treating non-small cell lung cancer

目的评价培美曲塞联合顺铂(PC方案)和多西他塞联合顺铂(DP方案)治疗非小细胞肺癌(NSCLC)的疗效。方法 78例NSCLC患者随机分为两组:A组38例,采用PC方案,B组40例,采用DP方案。比较两组近期疗效。结果A、B组有效率相仿(34.21%vs.42.50%)(P>0.05)。A、B组疾病控制率相仿(73.68%vs.80.00%)(P>0.05)。A组主要不良反应如恶心呕吐(47.36%vs.75.00%)、肝功能异常(39.47%vs.72.50%)、中性粒细胞减少(36.84%vs.75.00%)和脱发(10.53%vs.90.00%)的发生率均低于B组(P<0.05)。随访1年后,A、B组的生存率分别为26.31%和32.50%,中位生存期分别为5个月和11个月。结论 PC方案和DP方案治疗晚期NSCLC的近期疗效大致相仿,但是PC方案的不良反应发生率较低。

Objective To evaluate the efficacy of pemetrexed-cisplatin（PC scheme）and docetaxel race-cisplatin（DP scheme）in treating non-small cell lung cancer（NSCLC）.Methods A total of 78patients with advanced NSCLC was randomly divided into two groups A（treated with PC scheme,38cases）and B（treated with DP scheme,40cases）.The efficacy was compared between two groups.Results The effectiveness rate and disease control rate of group A and group B were similar（34.21% vs.42.50% and 73.68% vs.80.00%）（P〈0.05）.The incidence rates of major adverse reactions were lower in group A than those in group B,which included nausea and vomiting（47.36% vs.75.00%）,abnormal liver function（39.47%vs.72.50%）,neutropenia（36.84%vs.75.00%）and alopecia（10.53% vs.90.00%）.The one-year survival rates of groups of A and B were 26.31% and 32.50% and the median survival times of groups of A and B were 5 months and 11 months,respectively.Conclusion The short-term efficacy of PC scheme is similar to that of DP scheme in the treatment of advanced NSCLC.The incidence rates of major adverse reactions of patients treated with PC scheme are lower than those with DP scheme.